BIOLASE (NASDAQ:BIOL) Receives New Coverage from Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of BIOLASE (NASDAQ:BIOL) in a note issued to investors on Saturday. The brokerage set a “sell” rating on the medical technology company’s stock.

A number of other equities research analysts have also recently issued reports on BIOL. Benchmark restated a “speculative buy” rating and set a $0.40 price objective on shares of BIOLASE in a report on Tuesday, May 14th. Maxim Group cut BIOLASE from a “strong-buy” rating to a “hold” rating in a report on Friday, May 24th.

BIOLASE Stock Performance

BIOLASE stock opened at $0.08 on Friday. BIOLASE has a 52 week low of $0.04 and a 52 week high of $10.31. The company has a debt-to-equity ratio of 34.06, a quick ratio of 0.64 and a current ratio of 1.17. The stock has a market capitalization of $2.54 million, a P/E ratio of -0.01 and a beta of 0.74. The stock has a 50-day simple moving average of $0.15 and a 200 day simple moving average of $0.40.

BIOLASE (NASDAQ:BIOL) last posted its quarterly earnings results on Monday, May 13th. The medical technology company reported ($0.36) EPS for the quarter. BIOLASE had a negative return on equity of 1,782.73% and a negative net margin of 43.56%. The business had revenue of $10.13 million for the quarter.

Institutional Investors Weigh In On BIOLASE

An institutional investor recently raised its position in BIOLASE stock. Virtu Financial LLC increased its holdings in BIOLASE, Inc. (NASDAQ:BIOL) by 1,068.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 143,537 shares of the medical technology company’s stock after buying an additional 131,248 shares during the period. Virtu Financial LLC owned 0.43% of BIOLASE worth $27,000 as of its most recent filing with the Securities and Exchange Commission. 8.79% of the stock is currently owned by institutional investors and hedge funds.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.